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Precis
In the SARC021 trail, efficacy outcomes for older
patients with sarcoma did not significantly dif-
fer from those of younger patients with sar-
coma treated with first-line chemotherapy.
Older patients with sarcoma experienced more
toxicity than younger patients treated with
first-line chemotherapy.
Background: More than half of patients with soft tissue sarcoma (STS) are aged ≥65 years (older), however
contemporary data on the efficacy/safety of anthracycline chemotherapy in older patients with STS are lacking.
Methods: SARC021 randomized patients to receive first-line doxorubicin or doxorubicin plus evofosfamide. The
main aim of this study was to compare the outcome and safety of first-line anthracycline-based therapy in
older patients compared with those b65 years. IRB approval was obtained at all participating sites and this
research meets requirements for protection of human subjects.
Results: Of 640 patients, 209 (33%) were older, with a median age 70 (range 65–89) years. The median overall
survival (OS) was 16.7 months (95%CI: 13.2–20.0) in older patients compared to 20.1 months (95%CI: 16.9–
23.2) in those aged b65 years (n=431), HR 1.21 (95%CI: 0.99–1.48), p= .057. Themedian progression-free sur-
vival (PFS) in older patients was 6.3 months (95%CI: 5.8–7.2) compared to 6.0 (95%CI: 5.1–6.4) in those
b65 years, HR 0.86 (95%CI: 0.70–1.05), p = .14. Older patients had significantly more hematological (141
[67%] versus 208 [48%], p b .0001), non-hematological (131 [63%] versus 215 [50%], p = .0097) and ≥ Grade 3
adverse events (178 [85%] versus 299 [69%], p = .0002), compared to younger patients. More older patients
(30, 14%) stopped treatment due to adverse events compared to younger patients (22, 5%), p = .0001.
Conclusions: The efficacy of first-line anthracycline-based chemotherapy did not differ significantly between
older and younger advanced sarcoma patients. Significantly more older patients stopped chemotherapy due to
adverse events. These results provide a benchmark for daily clinical practice and future trials in older patients.











Soft tissue sarcomas (STS) are rare, heterogeneous tumors ofmesen-
chymal origin, that account for approximately 1–2% of all adult cancers
[1]. Almost half of STS are diagnosed in older patients aged ≥65 years,
with the highest incidence in patients aged ≥75 years. There are 13.5
new cases per 100,000 per year in the United States [2,3]. Advancing
age is a risk factor for the development of STS and an independent ad-
verse prognostic factor for survival in the metastatic setting [1,4–8].
Older patients are often diagnosed with higher-grade, higher-stage tu-
mors, and under-treatment is believed to contribute to worse survival
[6–8]. Older patients with STS are under-represented in clinical trials;
a recent analysis of 12 EORTC first-line chemotherapy trials found that
only 12% (n = 348) of participants were aged ≥65 years [9]. In view of
the ageing global population, contemporary, prospective data on the
outcomes of older patients with STS are needed to inform clinical
practice.
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Anthracycline-based schedules are the mainstay of treatment for
advanced STS (either as single agent or in combination). Systemic ther-
apies are used cautiously in older patients due to their toxicity; for ex-
ample, advancing age is a risk factor for anthracycline-associated
cardiotoxicity and pre-existing impaired renal function may preclude
the use of ifosfamide [10,11].
SARC021 was a randomized phase III trial of single-agent doxorubi-
cin versus doxorubicin plus the hypoxia-activated alkylating agent,
evofosfamide, as first-line therapy for advanced STS [12].
Themain aim of this studywas to compare the outcome and toxicity
of first-line anthracycline-based chemotherapy in older (≥65 years) and
younger patients with advanced sarcomas. Secondary aims included a
comparison of the efficacy and safety of doxorubicin and doxorubicin
plus evofosfamide (DE) in older patients and an evaluation of patients
≥75 years of age treated within the trial.
2. Materials and Methods
In this study, older patients were defined as those aged 65 years or
older. A retrospective analysis of the SARC021 clinical trial database
was performed to identify older patients and those aged b65 years. Pa-
tient demographics, clinical details and prior treatments were collected
for analysis. Response was defined according to Response Evaluation
Criteria In Solid Tumors (RECIST) version 1.1. Adverse events (AEs)
were grouped into four categories (hematological, non-hematological,
cardiac, and ≥ Grade 3 AEs) and graded according to National Cancer
Institute Common Terminology Criteria for Adverse Events version 4.0.
Cardiac functionwas assessed using eithermulti-gated radionuclide an-
giography (MUGA) or echocardiogram, and electrocardiogram (ECG), at
baseline, after completion of four cycles and at termination of doxorubi-
cin. A cardiac AE was defined as a drop in left ventricular ejection frac-
tion (LVEF) of 10% from baseline resulting in a LVEF of b55%, an
absolute LVEF of 45%, or a 20% decline in LVEF at any level.
Quality of life (QOL) assessments were performed at screening, on
Day 1 of each cycle (pre-dose), at termination of treatment and every
3 months during follow-up. QOL assessments were completed by pa-
tients only. Two QOL instruments were administered, the EuroQOL-
five dimension-five response level tool (EQ-5D-5 L) incorporating 5
items (mobility, self-care, usual activities, pain/discomfort and anxi-
ety/depression) and scored 1 (“no problem”) to 5 (“extreme prob-
lems”), and a 20-cm visual analog scale tool, the EuroQOL- visual
acuity scale EQ-VAS) (scored 0 “the worse health you can imagine” to
100 “the best health you can imagine”).
Descriptive statistics were used to compare baseline characteristics
of older patients with those aged b65 years. Kaplan-Meier curves were
used to summarize progression-free (PFS) and overall survival (OS) of
older patients and those aged b65 years with p-value calculated from
log-rank test. Response rates were compared between the two age
groups using Fisher's exact test. Cox models were used to generate
HRs and we also tested for interaction between treatment arm and
age group. Comparison of AEs between older patients and those
b65 years of age was similar to the analysis for older patients, but in-
stead of treatment, age ≥65 was included as the covariable of interest
in the analysis. We described the number of cycles administered for
older patients and those b65 years of age and number of patients who
stopped therapy due to AEs. Finally, 65 years is an arbitrary threshold
for defining status. To determine how sensitive the results are to this
value, we also did an analysis of patients over 75 years of age, defined
as ‘much older’.
Within the group of older patients, OS, PFS and response rate (RR)
were compared between those treated with doxorubicin versus
DE. Kaplan-Meier curves were used to summarize OS and PFS,
with p-value calculated using the log-rank test. Univariable Cox-
proportional hazards models were used to estimate hazard ratios,
with corresponding 95% confidence intervals. Multivariable models in-
cluded treatment arm, age, and all factors significant at the 0.05 level
in univariable analyses. Response rates of older patients between the
two treatment arms were compared using Fisher's exact test.
Univariable logistic regression models were used to estimate hazard
ratios, with corresponding 95% confidence intervals. Multivariable
models included arm, age, and all factors significant at the 0.05 level
in univariable analyses.
IRB approval was obtained at all participating sites and this research
meets requirements for protection of human subjects.
3. Results
The primary analysis of the SARC021 trial showed no significant dif-
ference in OS (HR 1·06, 95%CI: 0·88–1·29), or PFS (HR 0·85, 95%CI:
0·70–1·03) between patients treated with doxorubicin and DE (as pre-
viously published) [12].
Of 640 participants in the SARC021 trial, there were 209 patients
aged ≥65 years (33%) and 431 patients (67%) aged b65 years. Baseline
characteristics are summarized in Table 1. The median age of older pa-
tients at baseline was 70 (range 65–89) years, and the median follow-
up was 16.5 months. Patients aged b65 years commonly had a baseline
ECOG performance status (PS) of 0, whereas older patients more fre-
quently had PS of 1 (p= .001). Leiomyosarcomawas themost common
histological subtype in both age groups and undifferentiated pleomor-
phic sarcoma wasmore frequent in older patients (p= .006). Older pa-
tients were more likely to have received prior radiation (p = .04).
There was no statistically significant difference in median OS be-
tween patients aged b65 years (20.1 months, 95%CI: 16.9–23.2) and
older patients (16.7 months, 95%CI: 13.2–20.0), HR = 1.21 (95%CI:
Table 1








Age: Median (years) 53 70 –
Sex 0.021
Female 246 (57%) 99 (47%)
Male 185 (43%) 110 (53%)
Ethnicity 0.77
Hispanic or Latino 23 (5%) 10 (5%)
Not Hispanic or Latino 408 (95%) 199 (95%)
Race 0.28
White 385 (89%) 197 (94%)
Asian 13 (3%) 4 (2%)
Black or African American 22 (5%) 5 (2%)
Other 11 (3%) 3 (1%)
ECOG performance status 0.0011
0 267 (62%) 98 (47%)
1 160 (37%) 110 (53%)
2 3 (1%) 1 (0%)
Extent of disease 0.050
Locally advanced 57 (13%) 40 (19%)
Metastatic disease 374 (87%) 169 (81%)
Tumor grade 0.46
High grade 288 (67%) 130 (62%)
Intermediate grade 130 (30%) 74 (35%)
High/intermediate grade 12 (3%) 4 (2%)
Low grade 1 (0%) 0 (0%)
Histology 0.0056
Leiomyosarcoma 153 (35%) 77 (37%)
Liposarcoma 75 (17%) 36 (17%)
Undifferentiated pleomorphic
sarcoma
41 (10%) 38 (18%)
Other 162 (38%) 58 (28%)
Prior radiotherapy 0.043
Yes 148 (34%) 120 (57%)
No 283 (66%) 89 (43%)
Prior neo(adjuvant) chemotherapy 0.66
Yes 27 (6%) 15 (7%)
No 404 (94%) 194 (93%)
Bold values indicate a significant p-value b0.05
464 E. Younger et al. / Journal of Geriatric Oncology 11 (2020) 463–469
0.99–1.48), p = .057 (Fig. 1). No significant difference in median PFS
was observed between patients aged b65 years (6.0 months, 95%CI:
5.1–6.4) compared to older patients (6.3 months, 95%CI: 5.8–7.2), HR
= 0.86 (95%CI: 0.70–1.05), p = .14 (Fig. 2). No significant difference
in response rate was observed between those b65 years (103, 24%)
compared to older patients (46, 22%), p= .60. Onmultivariable analysis
(Tables 2 and 3), PS of 1 or 2 was associatedwith significantly worse OS
than PS 0 (HR 1.92 [1.57, 2.32], p b .001) and significantlyworse PFS (HR
1.47, [1.20, 1.79], p b .001). Patients with pleomorphic sarcoma had
significantly worse OS compared to those with leiomyosarcoma (HR
1.61 [1.18–2.20], p = .002), as did ‘other’ subtypes compared to
leiomyosarcoma (HR 1.65 [1.31–2.08], p b .001).
As shown in Table 4, hematological (anemia, neutropenia, thrombo-
cytopenia) and non-hematological (fatigue, reduced appetite, diarrhea)
AEs were significantly more common in older patients. There were 494
patients with at least one follow-up echocardiogram. There was no sig-
nificant difference in cardiotoxicity between those b65 years (35, 8%)
and older patients (20, 20%), p = .60. Dexrazoxane was administered
Fig. 1. OS older patients aged ≥65 years vs. patients aged b65 years.
Fig. 2. PFS older patients aged ≥65 years vs. patients aged b65 years.
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to 22 patients b65 years and 12 in the older age group. Two of these pa-
tients experienced cardiotoxicity (both b65 years). AEs of Grade ≥ 3
were significantly more common in older patients (p = .0002). The
most common Grade 3 AE was anemia (b65 years: n = 125 [30%],
older: n = 83 [40%]) and most frequent Grade 4 AE was neutropenia
(b65 years: n = 55 [13%], older: n = 47 [23%]).
Both age groups received a median of 6 cycles (range 0–6). In those
b65 years, 154 (36%) underwent dose reductions compared to 93 (44%)
in the older age group, p = .7. Significantly more older patients (30,
14%) stopped therapy due to AEs compared to those b65 years (22,
5%), p= .0001. Baseline ECOG performance status (PS) of 1 or 2 was as-
sociated with significantly greater hematologic AEs compared to PS 0
(OR 1.68 [1.22, 2.33], p = .002) and remained significant in multivari-
able analysis after accounting for age and treatment arm (OR 1.55
[1.11–2.17], p = .010). Patient age ≥ 65 years was also associated with
significantly more hematologic AEs compared with age b 65 years (OR
2.07 1.47–2.95, p b .001), and remained significant in multivariable
analysis after accounting for ECOG performance status and treatment
arm (OR 1.95 1.38–2.80, p b .001).
On univariable analysis, factors associated with higher non-
hematological AE were age ≥ 65 years (OR 1.57 1.12–2.21, p = .01),
DE combination treatment (OR 1.67 1.22–2.31, p = .02), baseline PS 1
or 2 (OR 2.00 [1.44, 2.78], p b .001) and prior radiation (OR 1.48 [1.06,
2.07], 0.021). On multivariable analysis, DE combination treatment
arm, ECOG performance status of 1 or 2 and prior radiation remained
independently associated with non- hematological AEs (p = .001, p b
.001 and p= .015 respectively), however older age was no longer asso-
ciated with non-hematological AEs when controlling for these variables
(p = .072).
Baseline PS of 1 or 2was associatedwith significantlymoreGrade ≥ 3
AEs than PS 0, HR 1.93 (1.30, 2.89), p = .001.
In patients aged b65 years, QOL data were available for 127 patients
(29%) at baseline and 131 patients (30%) at study termination. For older
patients, QOL datawere available at baseline in 61 (29%) and 57 (27%) at
study termination. Patients aged b65 years had a significantly higher
(worse) mean anxiety/depression score (2.04, SD 0.98) at baseline
compared with older patients (1.62, SD 0.78), p = .004. Older patients
had numerically higher (worse) mean mobility score (1.82, SD 1.14)
at termination of the study compared to b65 years (1.5, SD 0.78), p =
.063. There were no differences in EQ-VAS scores between patients
aged b65 years and older patients.
The comparison of 103 older patients treated with doxorubicin and
106 treated with DE, demonstrated that the baseline characteristics
were well-balanced between the arms (Table 5). There was no signifi-
cant difference in median OS between the doxorubicin (17.0 months,
95%CI: 12.9–20.6) and the DE arm (16.2 months, 95%CI: 11.5–23.0),
Table 2
Overall survival: cox proportional hazard regression.
Univariable Multivariable
HR (95% CI) P value HR (95% CI) P value
Age ≥ 65 1.21 (0.99–1.48) 0.057 1.08 (0.87–1.31) 0.515
Doxorubicin plus Evofosfamide (vs Dox alone) 1.08 (0.89–1.3) 0.451 1.11 (0.92–1.34) 0.293
ECOG 1 or 2 (vs ECOG 0) 2.02 (1.66–2.44) b0.001 1.92 (1.57–2.33) b0.001
Continuous (vs bolus) 0.85 (0.64–1.14) 0.291
Locally advanced (vs distant metastatic) 0.92 (0.7–1.21) 0.539
Prior radiation (vs No) 0.92 (0.75–1.12) 0.380
Histology (vs Leiomyosarcoma)⁎
Liposarcoma 1.15 (0.86–1.55) 0.345 1.12 (0.83–1.50) 0.457
Pleomorphic sarcoma/malignant fibrous
histocytoma
1.68 (1.23–2.29) 0.001 1.61 (1.18–2.20) 0.002
Other 1.76 (1.4–2.22) b0.001 1.65 (1.31–2.08) b0.001
Gender male (vs female) 1.12 (0.93–1.36) 0.235
⁎ Likelihood ratio test p value ≤.001, therefore included in multivariable analysis.
Table 3
Progression Free Survival: Cox Proportional Hazard Regression.
Univariable Multivariable
HR (95% CI) P value HR (95% CI) P value
Age ≥ 65 0.86 (0.70–1.05) 0.140 0.78 (0.63–0.96) 0.020
Doxorubicin plus Evofosfamide (vs Dox alone) 0.86 (0.71–1.04) 0.128 0.84 (0.70–1.02) 0.086
ECOG 1 or 2 (vs ECOG 0) 1.38 (1.14–1.67) 0.001 1.47 (1.2–1.79) b0.001
Continuous (vs bolus) 0.89 (0.67–1.18) 0.433
Locally advanced (vs distant metastatic) 0.92 (0.7–1.22) 0.562
Prior radiation (vs No) 0.9 (0.74–1.1) 0.296
Histology (vs Leiomyosarcoma)⁎




Other 1.14 (0.84–1.57) 0.398
Gender male (vs female) 1.18 (0.97–1.42) 0.094
⁎ Likelihood ratio test p value = .98, therefore not included in multivariable analysis.
Table 4
Adverse events (all grades): patients b65 years versus older patients.
Patients b65 years old
(n = 431)




No 205 (48%) 67 (32%)
Yes 208 (48%) 141 (67%)
Non-Hematological AE 0.0097
No 198 (46%) 77 (37%)
Yes 215 (50%) 131 (63%)
Cardiac AE 0.60
No 295 (68%) 144 (69%)
Yes 35 (8%) 20 (10%)
≥ Grade 3 AE 0.0002
No 114 (26%) 30 (14%)
Yes 299 (69%) 178 (85%)
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HR 1.08 (0.89–1.3), p = .45. There was no significant difference in me-
dian PFS between the doxorubicin (6.1 months, 95%CI: 4.7–7.2) and the
DE arm (6.5 months, 95% CI 4.9–8.2), HR 1.08 (0.89–1.3) and p = .45
(Fig. 3). There was no significant difference in response rate between
the doxorubicin (19, 18%) and the DE arm (27, 25%), p = .22. As
shown in Table 6, hematological AEs occurred with similar frequency
in both treatment arms. Non-hematological AEs were more common
in the DE arm (p = .0014). The most frequent non-hematological AEs
were fatigue, nausea, stomatitis and constipation. There was no signifi-
cant difference in cardiac AEs between the doxorubicin (8, 8%) and DE
arm (12, 11%), p = .40. Grade 3 and 4 AEs occurred in 85 patients
(83%) in the doxorubicin arm and 93 patients (88%) in the DE arm,
p = .37. Significantly more patients treated with DE (58, 55%) had a
dose reduction compared to doxorubicin (35, 34%), p = .003.
Thirty-nine patients aged ≥75 years participated in the SARC021 trial
(Dox n=19, DE n=20), and 30 of these patients were deceased at the
time of analysis. The median OS of ‘much older’ patients was
16.7 months (95%CI: 7.5–23.0) and the median PFS was 4.4 months
(95%CI: 2.8–6.5). There was no significant difference in median OS and
PFS between ‘much older’ patients treated with doxorubicin and DE.
Nine of these 39 patients had a radiological response (doxorubicin
n = 5, DE n = 4, p = .72). Five patients discontinued treatment due
to toxicity (doxorubicin n = 1, DE n = 4).
4. Discussion
This SARC021 sub-analysis demonstrated no significant difference in
median OS, PFS and response rate between older patients and patients
aged b65 years. However, older participants experienced significantly
more hematological and grade ≥ 3 AEs, and were more likely to stop
treatment early. Our study also showed no significant difference in me-
dian OS, PFS and response rate between older patients treated with
doxorubicin compared with doxorubicin plus evofosfamide, however,
non-hematological AEs were significantly more common in the combi-
nation arm. There are few contemporary data regarding the safety and
efficacy of first-line anthracycline-based therapy in advanced soft tissue
sarcomas. The available studies are of historic cohorts and do not repre-
sent current diagnostic classification and salvage systemic therapy
schedules [9,13]. Furthermore, compared to previous studies, our
study is strengthened by central pathology review and consistent
treatment within a prospective clinical trial.
Table 5








Age: Median (years) 70 (65–84) 69 (65–89) 0.29
Sex 0.96
Female 49 (48%) 50 (47%)
Male 54 (52%) 56 (53%)
Ethnicity 0.55
Hispanic or Latino 4 (4%) 6 (6%)
Not Hispanic or Latino 99 (96%) 100 (94%)
Race 0.51
White 95 (92%) 102 (96%)
Asian 2 (2%) 2 (2%)
Black or African American 4 (4%) 1 (1%)
Other 2 (2%) 1 (1%)
ECOG performance status 0.39
0 52 (50%) 46 (43%)
1 51 (50%) 59 (56%)
2 0 (0%) 1 (1%)
Extent of disease 0.65
Locally advanced 82 (80%) 87 (82%)
Metastatic disease 21 (20%) 19 (18%)
Tumor grade 1.00
High grade 64 (62%) 66 (62%)
Intermediate grade 36 (35%) 38 (36%)
High/intermediate grade 2 (2%) 2 (2%)
Histology 0.58
Leiomyosarcoma 35 (34%) 42 (40%)
Liposarcoma 15 (15%) 21 (20%)
Undifferentiated pleomorphic
sarcoma
19 (18%) 19 (18%)
Other 34 (33%) 23 (22%)
Prior radiotherapy 0.75
Yes 45 (44%) 44 (42%)
No 58 (56%) 62 (58%)
Prior neo(adjuvant) chemotherapy 0.39
Yes 9 (9%) 6 (6%)
No 94 (91%) 100 (94%)
Fig. 3. PFS by treatment arm among older patients aged ≥65 years.
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Physiological changes associated with ageing can impact pharmaco-
kinetic and pharmacodynamic properties leading to an increased risk of
toxicity [14-16]. Many physicians are cautious to use combination che-
motherapy in older patients despite several solid tumor trials showing
that doublet chemotherapy can be used safely in carefully selected pa-
tients [17-19]. Predicting which patients are at greater risk of toxicity
is challenging due to significant inter-individual variability [13-16].
The G8 (Geriatric 8) assessment screening tool is currently recom-
mended by the Society of Geriatric Oncology (SIOG) to identify patients
who require comprehensive geriatric assessment (CGA) [20]. Manage-
ment of high-risk patients by a geriatrician-led multidisciplinary team
can improve tolerance to chemotherapy, although provision may be
limited by costs and resources [21]. Anemia and neutropenia were the
most commonly reported grade 3 and 4 AEs respectively. High rates of
hematological AEs in older patients are likely to reflect depleted bone
marrow reserves [16].
Older patients have been under-represented in clinical trials. One
third of patients in SARC021were older, which provided an opportunity
to better understand outcomes and toxicity in comparisonwith patients
aged b65 years. More clinical trials specifically for older patients are
needed, such as the EPAZ phase II randomized trial of pazopanib versus
doxorubicin as first-line treatment for older patients (≥60 years) with
advanced STS [22,23]. The median age of patients in the EPAZ trial was
71 (range 60–88) years [24]. Pazopanibwas non-inferior to doxorubicin
in terms of median PFS (4.4 versus 5.3 months) and OS (12.3 versus
14.3 months respectively) [24]. AEs were typical for known side effects.
The EPAZ doxorubicin arm (n=39) had slightly lower median PFS and
OS compared to older patients in our study. A recent study of older pa-
tients treatedwithin the randomized phase III trial of trabectedin versus
dacarbazine in pre-treated liposarcoma and leiomyosarcoma, demon-
strated the safety and efficacy of trabectedin in patients over the age
of 65 years [25]. Consequently, there is evidence to support the use of
palliative systemic therapies in older patients withmetastatic sarcomas.
Comprehensive QOL assessments should be incorporated as end-
points in trials, as patient reported outcomes are a vital component of
evaluation of the net clinical benefit of a treatment. Older patients
may consider QOL as more important than survival, compared with
younger patients [26]. Although QOL analysis in SARC021 did not iden-
tify significant differences between younger and older patients, EQ-5D-
5 L contains five questions and EQ-VAS only one measurement, which
may not adequately assess the complex interplay of STS and its treat-
ment on all aspects of daily functioning. Only patients with a good PS
were enrolled into SARC021, which may not represent the older popu-
lation in clinical practice. Very few patients completed QOL assessments
and interpretation of these data are limited.
This study provides a contemporary benchmark of first-line
anthracycline-based therapy in older patients with advanced soft tissue
sarcoma. Our data show that anthracycline-based chemotherapy
appears to be effective in older patients. However, the increased rates
of AEs in older patients highlight the need for less toxic treatments
and optimization of supportive care. Future studies should incorporate
geriatric assessment tools and evaluate whether alternative drugs or
schedules can be safely and effectively used in this population. Greater
attention should be given to QOL, in order to guide interpretation of
treatment efficacy and optimize patient care.
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